Cancer diagnostics company, Dxcover Limited, has published its latest data from clinical studies on earlier detection of aggressive cancers.
The study[i] involving over 980 patients suffering from non-specific symptoms associated with brain tumours has shown that the Dxcover® Brain Cancer Liquid Biopsy was able to detect 96% (45 out of 47) of patients with brain tumours, and identified all patients with Glioblastoma Multiforme - the most aggressive type of brain cancer.
Brain cancer is the most advanced application of the Glasgow-based company’s novel liquid biopsy platform for the early detection of cancer, but the company will also be publishing its capability across eight different cancers.
The new publication in Neuro-Oncology Advances, showed that Dxcover’s test is sensitive in detecting patients with brain cancer, regardless of tumour type. These groundbreaking results means that patients with non-specific symptoms, such as headaches, who have a positive test can be triaged to have fast-tracked brain scans, confirming their diagnosis earlier with potentially life-saving results. In doing so there is also the potential to bring significant savings to healthcare services worldwide. The company is attracting significant endorsement from leading clinicians across the globe.
Dan Orringer, Associate Professor, Department of Neurosurgery at Grossman School of Medicine in New York, said: “I have been impressed by the development and rigorous approach employed by the Dxcover team. The real-world data they have managed to collect within their prospective clinical study shows excellent clinical utility for the Dxcover Brain Cancer Liquid Biopsy.
“The Dxcover approach will have a significant impact on the lives of patients undergoing testing for brain tumours by enabling faster detection as well as faster rule out of non-cancerous patients aiding clinical decision making in a difficult area.”
Matthew Baker, Chief Technology Officer at Dxcover, said: “Detection of brain tumours via liquid biopsy has always been challenging due to the blood-brain barrier. This research shows the potential of our technology to revolutionise the clinical pathway by creating a triage system for patients displaying non-specific symptoms of brain cancer. By doing so, diagnosis will come at an earlier stage, leaving more clinical options for doctors to explore.”
Dr Paul Brennan, a consultant neurosurgeon at the University of Edinburgh, said: "This latest data from the Dxcover underscores the impressive performance of its blood test in identifying patients with a brain tumour from amongst a larger group of patients with non-specific symptoms. This test can support GP decision making about which patients to refer for rapid brain imaging. The Dxcover test is a critical tool in the drive to earlier cancer diagnosis. This rapid, low-cost test can play a vital role in the drive to recover NHS services from the effects of the COVID pandemic. "
